Dong-Wan Kim, Byoung Chul Cho, Krishna Pachipala, Sang-We Kim, Chih-Liang Wang, Gee-Chen Chang, Myung-Ju Ahn, Rosa Alvarez, Chao-Hua Chiu, José Trigo, Anna Estival, Sana D Karam, Cathy O'Brien, Hema Gowda, Haiyi Jiang, Julie E Bauman
INTRODUCTION: For patients with unresectable, stage III non-small-cell lung cancer (NSCLC), current standard of care is concurrent chemoradiotherapy (cCRT) followed by consolidation durvalumab. However, earlier initiation of durvalumab simultaneously with cCRT may increase antitumor activity relative to initiation after cCRT. The phase 1 CLOVER study (NCT03509012) evaluated durvalumab combined with cCRT in patients with advanced solid tumors; we report findings from the NSCLC cohort. METHODS: CLOVER comprised a dose-limiting toxicity (DLT) assessment part, followed by an expansion part...
April 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer